ABEONA THERAPEUTICS INC. Contracts & Agreements

Underwriting Agreement, dated May 3, 2024 (Filed With SEC on May 3, 2024)

Form of Pre-Funded Warrant (Filed With SEC on May 3, 2024)

Warrant to Purchase Common Stock, by and between Abeona Therapeutics, Inc. and Avenue Venture Opportunities Fund, L.P., dated as of January 8, 2024 (Filed With SEC on January 8, 2024)

Warrant to Purchase Common Stock, by and between Abeona Therapeutics, Inc. and Avenue Venture Opportunities Fund II, L.P., dated as of January 8, 2024 (Filed With SEC on January 8, 2024)

Loan and Security Agreement, by and among Abeona Therapeutics, Inc., MacroChem Corporation, Abeona Therapeutics LLC, Avenue Venture Opportunities Fund, L.P., as Agent, and Avenue... (Filed With SEC on January 8, 2024)

Supplement to the Loan and Security Agreement, by and among Abeona Therapeutics, Inc., MacroChem Corporation, Abeona Therapeutics LLC, Avenue Venture Opportunities Fund, L.P., as... (Filed With SEC on January 8, 2024)

Retention Bonus Letter, dated June 15, 2023, to Vishwas Seschadri, Ph.D (Filed With SEC on August 8, 2023)

Retention Bonus Letter, dated June 15, 2023, to Joseph Vazzano (Filed With SEC on August 8, 2023)

Retention Bonus Letter, dated June 15, 2023, to Brendon OMalley, Ph.D (Filed With SEC on August 8, 2023)

Form of Pre-Funded Warrant (Filed With SEC on July 3, 2023)

Securities Purchase Agreement, dated July 3, 2023 (Filed With SEC on July 3, 2023)

Form of Warrant (Filed With SEC on November 3, 2022)

Form of Pre-Funded Warrant (Filed With SEC on November 3, 2022)

Form of Registration Rights Agreement (Filed With SEC on November 3, 2022)

Securities Purchase Agreement dated November 3, 2022 (Filed With SEC on November 3, 2022)

License Agreement by and between Abeona Therapeutics Inc. and Ultragenyx Pharmaceutical Inc., dated May 16, 2022 (Filed With SEC on August 11, 2022)

Letter Agreement, dated February 28, 2022, between the Company and Joseph Vazzano (Filed With SEC on May 13, 2022)

Form of Securities Purchase Agreement between Abeona Therapeutics Inc. and the investors thereto, dated April 29, 2022 (Filed With SEC on May 2, 2022)

Form of Registration Rights Agreement by and among Abeona Therapeutics Inc. and the investors named therein, dated April 29, 2022 (Filed With SEC on May 2, 2022)

Letter Agreement, dated October 6, 2021, between the Company and Vishwas Seshadri (Filed With SEC on March 31, 2022)

Letter Agreement, dated September 16, 2021, between the Company and Brendan OMalley (Filed With SEC on March 31, 2022)

Settlement Agreement and Mutual Release, dated November 12, 2021, between the Company and REGENXBIO Inc (Filed With SEC on March 31, 2022)

Underwriting Agreement, dated December 17, 2021 (Filed With SEC on December 17, 2021)

Form of Warrant (Filed With SEC on December 17, 2021)

Amendment No. 1 to Open Market Sale Agreement, dated November 19, 2021, amending the Open Market Sale Agreement, by and between the Company and Jefferies LLC, dated August 17, 2018 (Filed With SEC on November 19, 2021)

Letter Agreement, dated August 10, 2021, between the Company and Edward Carr (Filed With SEC on November 15, 2021)

Amended and Restated Letter Agreement, dated January 27, 2021, between the Company and Michael Amoroso (Filed With SEC on May 17, 2021)

Letter Agreement, dated March 19, 2021, between the Company and Michael Amoroso (Filed With SEC on May 17, 2021)

Letter Agreement, dated October 26, 2020, between Abeona Therapeutics Inc. and Michael Amoroso (Filed With SEC on October 30, 2020)

Form of Indemnification Agreement (Filed With SEC on October 16, 2020)

Amendment No. 3, dated April 14, 2020, to Letter Agreement, dated January 2, 2020, between the Company and Steven H. Rouhandeh (Filed With SEC on August 10, 2020)

Offer Letter between Abeona Therapeutics Inc. and Edward Carr, dated June 18, 2020 (Filed With SEC on June 23, 2020)

Letter Agreement, dated January 2, 2020, between the Company and Steven H. Rouhandeh (Filed With SEC on May 6, 2020)

Amendment No. 1, dated March 6, 2020, to Letter Agreement, dated January 2, 2020, between the Company and Steven H. Rouhandeh (Filed With SEC on May 6, 2020)

Letter Agreement, dated March 13, 2020, between the Company and Christine Berni Silverstein (Filed With SEC on May 6, 2020)

Amendment No. 2, dated March 31, 2020, to Letter Agreement, dated January 2, 2020, between the Company and Steven H. Rouhandeh (Filed With SEC on May 6, 2020)

Offer Letter, dated April 15, 2020, between Abeona Therapeutics Inc. and Brian J.G. Pereira, M.D (Filed With SEC on April 21, 2020)

Description of Capital Stock of Abeona Therapeutics Inc (Filed With SEC on March 16, 2020)

Underwriting Agreement, dated December 20, 2019, among the Company, Jefferies LLC and SVB Leerink LLC (Filed With SEC on December 23, 2019)

Form of Pre-Funded Warrant (Filed With SEC on December 23, 2019)

Letter Agreement regarding Certain Purchaser Rights, dated December 20, 2019, among the Company, Biomedical Value Fund, L.P., Biomedical Offshore Value Fund, Ltd., and GEF-SMA, L.P (Filed With SEC on December 23, 2019)

Letter Agreement, dated September 12, 2019, amending Offer Letter between the Company and Joo Siffert, M.D., dated February 11, 2019 (Filed With SEC on November 12, 2019)

Letter Agreement, dated September 12, 2019, amending Offer Letter between the Company and Christine Berni Silverstein, dated January 8, 2019 (Filed With SEC on November 12, 2019)

Letter Agreement, dated September 12, 2019, amending Offer Letter between the Company and Edward Carr, dated November 9, 2018 (Filed With SEC on November 12, 2019)

First Amendment to License Agreement, dated November 1, 2019, between the Company and REGENXBIO Inc (Filed With SEC on November 12, 2019)

License Agreement, dated November 4, 2018, between the Company and REGENXBIO Inc (Filed With SEC on March 18, 2019)

Offer Letter, dated February 11, 2019, by and between Abeona Therapeutics Inc. and Joo Siffert, M.D (Filed With SEC on February 13, 2019)

Offer Letter, dated January 8, 2019, by and between Abeona Therapeutics Inc. and Christine Berni Silverstein (Filed With SEC on January 10, 2019)

Letter Agreement between Abeona Therapeutics, Inc. and Joo Siffert, M.D., dated September 28, 2018 (Filed With SEC on November 30, 2018)

Letter Agreement between Abeona Therapeutics, Inc. and Joo Siffert, M.D., dated November 29, 2018 (Filed With SEC on November 30, 2018)

Separation Agreement between Abeona Therapeutics, Inc. and F. Carsten Thiel, Ph. D., dated November 29, 2018 (Filed With SEC on November 30, 2018)

Offer Letter, effective October 19, 2018, by and between Abeona Therapeutics Inc. and Edward Carr (Filed With SEC on November 9, 2018)

Letter of Agreement dated October 5, 2018 by and between the Company and Stephen B. Thompson (Filed With SEC on October 9, 2018)

Letter of Agreement and General Release dated October 1, 2018 between the Company and Jeffrey Davis (Filed With SEC on October 5, 2018)

Open Market Sale Agreement, dated August 17, 2018, by and between the Company (Filed With SEC on August 20, 2018)

Employment Agreement dated March 29, 2018 between the Company and F. Carsten Thiel (Filed With SEC on May 10, 2018)

Underwriting Agreement between the Company and Jefferies LLC, as representative for the underwriters named therein, dated as of October 16, 2017 (Filed With SEC on October 17, 2017)

6,000,000 Shares Abeona Therapeutics Inc. UNDERWRITING AGREEMENT (Filed With SEC on October 28, 2016)

ABEONA THERAPEUTICS INC. Common Stock (par value $0.01 per share) At Market Issuance Sales Agreement (Filed With SEC on August 26, 2016)

INDEMNIFICATION AGREEMENT (Filed With SEC on August 15, 2016)

EMPLOYMENT AGREEMENT (Filed With SEC on November 16, 2015)

AGREEMENT AND PLANOF MERGER BY AND AMONG PLASMATECH BIOPHARMACEUTICALS,INC. AND PLASMATECH MERGER SUB,INC. AND ABEONA THERAPEUTICSLLC AND MEMBER REPRESENTATIVE DATED AS OF MAY... (Filed With SEC on August 14, 2015)

PLASMATECH BIOPHARMACEUTICALS, INC. COMMON STOCK PURCHASE AGREEMENT (Filed With SEC on August 14, 2015)

SECURITIESPURCHASE AGREEMENT (Filed With SEC on August 14, 2015)

PURCHASE AGREEMENT (Filed With SEC on August 3, 2015)

AMENDMENT TO LICENSE AGREEMENT (Filed With SEC on March 31, 2015)

PLASMATECH BIOPHARMACUETICALS, INC. Unsecured Grid Note (Filed With SEC on December 3, 2014)

UNDERWRITING AGREEMENT between PLASMATECH BIOPHARMACEUTICALS, INC. and AEGIS CAPITAL CORP., as Representative of the Several Underwriters (Filed With SEC on November 6, 2014)

UNDERWRITING AGREEMENT between PLASMATECH BIOPHARMACEUTICALS, INC. and AEGIS CAPITAL CORP., as Representative of the Several Underwriters (Filed With SEC on October 24, 2014)

FORM OF WARRANT AGENCY AGREEMENT (Filed With SEC on October 24, 2014)

SHARE EXCHANGE AGREEMENT (Filed With SEC on October 23, 2014)

LICENSE AGREEMENT (Filed With SEC on September 24, 2014)

ACCESS Pharmaceuticals, Inc. 1325 Avenue of the Americas, 27th Floor New York, New York10019 (Filed With SEC on September 24, 2014)

EXHIBIT 10.33[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED.ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES... (Filed With SEC on August 14, 2013)

PREFERRED STOCK AND WARRANT PURCHASE AGREEMENT by and among Access Pharmaceuticals, Inc. and the parties named herein on Schedule 1, as Purchasers October 25, 2012 (Filed With SEC on October 26, 2012)

INVESTOR RIGHTS AGREEMENT (Filed With SEC on October 26, 2012)

COMMON STOCK PURCHASE WARRANT To Purchase [100% X (Issue Amount)/(Conversion Price)] Shares of Common Stock of ACCESS PHARMACEUTICALS, INC. (Filed With SEC on October 26, 2012)

CERTIFICATE OF DESIGNATIONS, RIGHTS AND PREFERENCES of SERIES B CUMULATIVE CONVERTIBLE PREFERRED STOCK of ACCESS PHARMACEUTICALS, INC. (Filed With SEC on October 26, 2012)

ACCESS NEWS (Filed With SEC on October 25, 2012)

SECURITIES PURCHASE AGREEMENT (Filed With SEC on November 10, 2011)

EXHIBIT 10.2 [FORM OF 2.5 YEAR WARRANT] (Filed With SEC on November 10, 2011)

EXHIBIT 10.3 [FORM OF 5 YEAR WARRANT] (Filed With SEC on November 10, 2011)

ACCESS PHARMACEUTICALS ANNOUNCES PRIVATE PLACEMENT OF $5.2 MILLION (Filed With SEC on November 7, 2011)

SECURITIES PURCHASE AGREEMENT (Filed With SEC on December 14, 2010)

COMMON STOCK PURCHASE WARRANT ACCESS PHARMACEUTICALS, INC. (Filed With SEC on December 14, 2010)

COMMON STOCK PURCHASE WARRANT ACCESS PHARMACEUTICALS, INC. (Filed With SEC on December 8, 2010)

SECURITIES PURCHASE AGREEMENT (Filed With SEC on December 8, 2010)

HUDSON SECURITIES, INC. LETTERHEAD December ___, 2010 (Filed With SEC on December 8, 2010)

COMMON STOCK PURCHASE WARRANT ACCESS PHARMACEUTICALS, INC. (Filed With SEC on November 23, 2010)

SECURITIES PURCHASE AGREEMENT (Filed With SEC on November 23, 2010)

HUDSON SECURITIES, INC. LETTERHEAD November ___, 2010 (Filed With SEC on November 23, 2010)

COMMON STOCK PURCHASE WARRANT ACCESS PHARMACEUTICALS, INC. (Filed With SEC on November 15, 2010)

AMENDMENTTO RIGHTS AGREEMENT (Filed With SEC on March 23, 2010)

EMPLOYMENTAGREEMENT (Filed With SEC on February 8, 2010)

SECURITIESPURCHASE AGREEMENT (Filed With SEC on January 21, 2010)

COMMONSTOCK PURCHASE WARRANT ACCESSPHARMACEUTICALS, INC. (Filed With SEC on January 21, 2010)

SECURITIESPURCHASE AGREEMENT (Filed With SEC on January 15, 2010)

COMMONSTOCK PURCHASE WARRANT ACCESSPHARMACEUTICALS, INC. (Filed With SEC on January 15, 2010)

AGREEMENTAND PLAN OF MERGER DATED ASOF JULY 9, 2008, BY ANDAMONG ACCESSPHARMACEUTICALS, INC., MACMACQUISITION CORP. AND MACROCHEMCORPORATION (Filed With SEC on August 14, 2008)

AMENDMENT TO EMPLOYMENTAGREEMENT (Filed With SEC on May 20, 2008)

_____________________________________________________________________________ PREFERRED STOCK AND WARRANT PURCHASE AGREEMENT by and among Access Pharmaceuticals, Inc. and the... (Filed With SEC on March 11, 2008)

INVESTOR RIGHTS AGREEMENT (Filed With SEC on March 11, 2008)

COMMON STOCK PURCHASE WARRANT To Purchase [50% X (Issue Amount)/(Conversion Price)] Shares of Common Stock of ACCESS PHARMACEUTICALS, INC. (Filed With SEC on March 11, 2008)

DIRECTOR DESIGNATION AGREEMENT (Filed With SEC on March 11, 2008)

_____________________________________________________________________________ (Filed With SEC on March 11, 2008)

AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT (Filed With SEC on March 11, 2008)

EMPLOYMENT AGREEMENT (Filed With SEC on March 11, 2008)

AMENDMENT TO 7.0% (SUBJECT TO ADJUSTMENT) CONVERTIBLE PROMISSORY NOTES DUE OCTOBER 26, 2007 (Filed With SEC on November 14, 2007)

AMENDMENT TO AMENDED AND RESTATED 7.5% SECURED CONVERTIBLE PROMISSORY NOTE DUE OCTOBER 25, 2007 (Filed With SEC on November 14, 2007)

AGREEMENT AND PLAN OF MERGER DATED AS OF APRIL 18, 2007, BY AND AMONG ACCESS PHARMACEUTICALS, INC., SOMANTA ACQUISITION CORPORATION, SOMANTA PHARMACEUTICALS, INC., SOMANTA... (Filed With SEC on April 23, 2007)

AGREEMENT AND PLAN OF MERGER DATED AS OF APRIL 18, 2007, BY AND AMONG ACCESS PHARMACEUTICALS, INC., SOMANTA ACQUISITION CORPORATION, SOMANTA PHARMACEUTICALS, INC., SOMANTA... (Filed With SEC on April 19, 2007)

SECURITY AGREEMENT (Filed With SEC on June 16, 2006)

ACCESSPHARMACEUTICALS, INC. 7.5% SECURED CONVERTIBLEPROMISSORY NOTE (Filed With SEC on June 16, 2006)

COMMON STOCKPURCHASE WARRANT To Purchase Shares of Common Stock of ACCESSPHARMACEUTICALS, INC. (Filed With SEC on June 16, 2006)

INVESTOR RIGHTSAGREEMENT (Filed With SEC on June 16, 2006)

AMENDMENT TORIGHTS AGREEMENT (Filed With SEC on June 16, 2006)

SEPARATIONAGREEMENT (Filed With SEC on May 1, 2006)

EMPLOYMENTAGREEMENT (Filed With SEC on May 1, 2006)

BACKGROUND (Filed With SEC on May 1, 2006)

LICENSE AGREEMENT (Filed With SEC on May 1, 2006)

AMENDMENT TORIGHTS AGREEMENT (Filed With SEC on May 1, 2006)

AMENDMENT TO 7.0%(SUBJECT TO ADJUSTMENT) CONVERTIBLE PROMISSORY NOTES DUE SEPTEMBER 13, 2005 (Filed With SEC on May 1, 2006)

Ex-10.35 Separation Agreement between Kerry P. Gray and the Registrant, dated as of May 10,2005 (Filed With SEC on May 31, 2005)

Ex-10.36 Letter Agreement between Rosemay Mazanet, M.D., Ph.D, dated as of May 10, 2005 (Filed With SEC on May 31, 2005)

Category

Industry

Companies

Contracts

ABEONA THERAPEUTICS INC. Contracts & Agreements